# Enovis account plan

> Enovis (NYSE: ENOV) is a US medical technology company in orthopedic implants and recovery devices, with FY2025 net sales of $2,248.0 million.

## At a glance

Enovis Corporation (NYSE: ENOV), the former Colfax, develops, manufactures and distributes medical devices for reconstructive surgery, rehabilitation, pain management and physical therapy. It sells to orthopedic specialists, surgeons, physical therapists and retail consumers through distributors, direct salespeople and direct-to-patient channels, with approximately 42% of FY2025 net sales from outside the U.S. In FY2025 net sales were $2,248.0 million (+6.7%) and Adjusted EBITDA $403.0 million, while goodwill impairments of $1,049.8 million produced a net loss of $(1,183.6) million. It employed approximately 7,802 people at December 31, 2025.

## Business units

- **Prevention & Recovery (P&R)** (51% of FY2025 net sales ($1,137.0 million)): Sells orthopedic bracing, hot and cold therapy, bone growth stimulators, electrical stimulators and physical therapy products under the DonJoy, Aircast and Chattanooga brands; approximately 67% of its revenues are in the U.S. The Dr Comfort divestiture in October 2025 cut reported sales, but Q3 2026 sales grew 3.0% on existing businesses with an 18.2% Adjusted EBITDA margin. Led by Terry D. Ross, Group President.
- **Reconstructive (Recon)** (49% of FY2025 net sales ($1,111.1 million)): Develops knee, hip, shoulder, elbow, foot, ankle and finger implants with instrumentation and enabling technologies for orthopedic surgeons and health systems worldwide, built partly through the Lima acquisition. Net sales grew 10% in FY2025 and 8.2% to $885.0 million in the first nine months of 2026, with share gains from the Nebula hip stem and shoulder products. Led by Louis Vogt, Group President.

## Strategic priorities

- **Innovation-led growth in Recon**: The strategy is "accelerating growth through innovation, expanding market presence in both established and emerging markets", with a pipeline of new product introductions planned for the next 24 months.
- **Enabling technology and robotics**: Enovis plans to bring a knee robot to market within 2 years after acquiring eCential Robotics, alongside its ARVIS Augmented Reality System, and adds a $4 million investment in enabling-technology R&D talent in Q4 2026.
- **Ambulatory surgery centers**: Management sees changing the trajectory of its full offering in ASCs over the next 3 to 5 years as a key opportunity; over 25% of primary knees are now in the ASC.
- **Operating model and discipline**: Since CEO Damien McDonald joined in March 2025, priorities are commercial execution and innovation, operational excellence and financial discipline, run through the Enovis Growth Excellence (EGX) system.
- **Cash generation**: For 2027 the CFO targets at least 50% free cash flow conversion and $100 million of cash generation, with 2026 the last big year of Lima integration investment.

## Latest results

In Q3 2026 (quarter ended October 2, 2026) net sales were $558.7 million, up 1.8% reported and 4.6% organic, with Recon up 6.0% and P&R down 1.9% after the Dr. Comfort divestiture. Gross margin rose to 60.8% from 59.9%, helped by tariff refunds, and Adjusted EBITDA was $103.5 million (18.5% margin). Net income was $3.4 million against a $(570.9) million loss a year earlier, which carried a goodwill impairment. Nine-month net sales were $1,730.7 million (+3.5%). The 2026 guidance was narrowed to revenue of $2.32-2.35 billion with about 5% organic growth, and Adjusted EBITDA guidance raised to $428-438 million.

## Investments and deals

- **eCential Robotics acquisition**: A securities purchase agreement was signed on September 28, 2026 to acquire eCential Robotics SAS for an enterprise value of approximately €155.0 million, plus up to €35.0 million on milestones; closing is expected in Q4 2026.
- **Surgical instrument capex**: Capex was $197.4 million in 2025, driven by surgical implant instruments for Recon growth, and $133.2 million in the first nine months of 2026.
- **Bolt-on acquisitions and divestitures**: Seven 2025 transactions totalled $36.9 million (distributors, businesses and IP), while Dr Comfort was sold in October 2025 for up to $60 million.
- **Share buyback**: On November 2, 2026 the Board approved a program to repurchase up to $200 million of shares, replacing the $100 million authorisation.
- **R&D in surgical technology**: Recon R&D rose to $83.3 million in 2025 from $55.6 million, invested in surgical productivity solutions and computer-assisted surgery technologies.

## Challenges and risks

- **Goodwill impairments**: A $1,049.8 million goodwill impairment in 2025, caused by the decline in share price and market capitalisation, drove a net loss; further declines could trigger more impairments.
- **Volatile markets**: Management describes a choppy market with cancellations, scheduling and co-pay pressure; international P&R in France and Germany is under pressure and the Middle East conflict was a 100 basis point headwind to international growth in Q3 2026.
- **Tariffs and cost inflation**: U.S. tariffs announced in early 2025 raised input costs, and Recon gross margin fell 150 basis points in Q3 2026 on mix and cost inflation.
- **Integration and leverage**: Lima integration costs continue ($9.2 million in Q3 2026); net leverage was 2.9x and eCential will add about 0.5 turn.
- **Regulation and legal exposure**: EU MDR recertification, reimbursement pressure and a False Claims Act investigation of a former independent distributor are named risks.

## What leadership says

> "Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline." — Damien McDonald, Chief Executive Officer, Q3 2026 earnings release, 2026-11-05

> "We expect to bring the knee robot to market within 2 years and shoulder to follow soon thereafter." — Damien McDonald, Chief Executive Officer, Q3 2026 earnings call, 2026-11-05

> "our focus is really on gaining market share and candidly, not being a victim to the market." — Damien McDonald, Chief Executive Officer, Q3 2026 earnings call, 2026-11-05

> "Since I joined 12 months ago, we have made meaningful changes to our operating model and senior leadership teams, implemented more rigor around daily management and changed company incentive plans to align with our strategic objectives." — Damien McDonald, Chief Executive Officer, Q1 2026 earnings call, 2026-05-08


## Where a supplier can help

- **Robotics and navigation engineering**: Tied to the enabling technology priority and the eCential acquisition: engineering, software and component partners can help bring the knee robot to market within 2 years.
- **ASC go-to-market support**: Tied to the ASC priority: market data, contracting and sales enablement tools can help Enovis target corporate and owner-operated ASCs.
- **Supply chain cost reduction**: Tied to the tariffs and cost inflation challenge: sourcing, freight and lower-cost manufacturing options can protect margins.
- **Regulatory compliance services**: Tied to the regulation challenge: EU MDR certification and compliance services fit a company still working towards MDR certification.
- **Sales force effectiveness**: Tied to the operating model priority: account targeting, pricing and training tools support the EGX-driven push on account acquisition and penetration.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1420800/000142080026000012/cfx-20251231.htm)

Annual report · 2026-02-26

- Enovis is a US medical technology company (NYSE: ENOV) reporting two segments, Prevention & Recovery (P&R) and Reconstructive (Recon), covering the patient care continuum from injury prevention to joint replacement and rehabilitation.
- FY2025 net sales were $2,248.0 million, up 6.7%; existing businesses added $123.5 million (5.9%) and foreign currency $30.0 million, while divestitures removed $17.3 million. Sales mix was 51% P&R and 49% Recon.
- Gross profit margin rose 380 basis points to 59.8%; Adjusted EBITDA (non-GAAP) was $403.0 million, a 17.9% margin. GAAP net loss was $(1,183.6) million, driven by a $1,049.8 million non-cash goodwill impairment tied to the fall in the share price.
- Recon net sales grew 10% to $1,111.1 million (Adjusted EBITDA margin 21.6%), with R&D up to $83.3 million as the segment invests in surgical productivity solutions and computer-assisted surgery technologies.
- P&R net sales were $1,137.0 million (Adjusted EBITDA margin 14.3%), sold under DonJoy, Aircast and Chattanooga; the Dr Comfort Footcare Solutions U.S. operations were sold to Promus Equity Partners in October 2025 for up to $60 million.
- Approximately 42% of net sales come from operations outside the U.S., mostly Europe; the company employed approximately 7,802 people, 5,695 of them outside the U.S.
- Seven small 2025 transactions totalled $36.9 million (three distributors, two businesses, two IP purchases); integration of Lima (acquired January 2024 for $865.6 million) continued, with $39.4 million of Lima integration costs in 2025.
- Balance sheet: the credit agreement was amended on December 8, 2025 (Revolver up to $1.1 billion, Term Loan $700 million, maturity December 8, 2030); at year-end $157.2 million Revolver, $688 million Term Loan and $452 million of 3.875% 2028 convertible notes were outstanding.
- Leadership: Damien McDonald has been CEO since March 2025 (formerly CEO of LivaNova); Oliver Engert, a former McKinsey Senior Partner, became Chief Administrative Officer in January 2026.
- Key risks named: further goodwill impairment, tariffs, acquisition integration, indebtedness and the convertible notes, FDA and EU MDR regulation, reimbursement and DMEPOS competitive bidding, cyber incidents, and tax exposure from the ESAB separation.

### [Form 10-Q for the third quarter of 2026 (quarter ended October 2, 2026)](https://www.sec.gov/Archives/edgar/data/1420800/000142080026000054/cfx-20261002.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter ended October 2, 2026) net sales were $558.7 million, up 1.8%; existing businesses grew 4.6%, offset by a 2.5% hit from the Dr. Comfort divestiture and 0.3% from currency. Nine-month sales were $1,730.7 million, up 3.5%.
- GAAP net income was $3.4 million in Q3 versus a $(570.9) million loss a year earlier, when a $548.4 million goodwill impairment was booked; no impairment this year.
- Adjusted EBITDA (non-GAAP) was $103.5 million, an 18.5% margin (Q3 2025: $94.8 million, 17.3%); nine-month Adjusted EBITDA $311.4 million, 18.0%.
- Recon Q3 net sales grew 6.0% to $273.3 million (existing businesses +6.3%) but gross margin fell 150 basis points to 65.6% on product and geographic mix and cost inflation.
- P&R Q3 net sales fell 1.9% to $285.4 million because of the Dr. Comfort sale, while existing businesses grew 3.0%; gross margin rose 280 basis points to 56.3%, helped by tariff refunds.
- A net tariff benefit of $4.7 million in Q3 came from $7.8 million of 2025 tariff refunds.
- Binding offer (August 31, 2026) to buy eCential Robotics SAS for an enterprise value of about €155.0 million (about €176.0 million upfront plus up to €35.0 million on milestones); closing expected in Q4 2026.
- The Board approved a new $200 million share repurchase program on November 2, 2026; nine-month operating cash flow rose to $170.5 million and $958 million was available on the Revolver.
- A False Claims Act civil investigation (US Attorney, Middle District of Tennessee) involving a former independent distributor now names the company among potential focuses.

### [Enovis Announces Third Quarter 2026 Results (earnings release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1420800/000142080026000052/q32026earningspressrelease.htm)

Interim report · 2026-11-05

- Enovis reported Q3 2026 net sales of $559 million, up 2% reported and 5% organic; Recon grew 6% reported and organic, while P&R declined 2% reported and grew 3% organic.
- Q3 net income was $3 million (0.6% of sales) and $0.02 per share; adjusted EBITDA was $104 million (18.5% of sales) and adjusted net earnings per diluted share $0.88.
- 2026 revenue guidance narrowed to $2.32-2.35 billion (previously $2.31-2.37 billion) with 5% organic growth (previously 4-6%).
- Adjusted EBITDA guidance raised to $428-438 million (from $425-435 million) and adjusted EPS guidance to $3.58-3.79 (from $3.52-3.73); free cash flow conversion expected at 25% or higher.
- Product-line growth in Q3: U.S. Bracing & Support $132.7 million (+4.5%), U.S. Reconstructive $135.3 million (+4.9%), International Reconstructive $138.0 million (+7.0% reported, 7.8% organic); International P&R $91.4 million (-1.2%).
- The Board approved a new share repurchase authorisation of up to $200 million, replacing the existing $100 million authorisation.
- CEO Damien McDonald cited "continued share gains in Recon and steady performance in Prevention & Recovery" and said the company is investing in technologies including the agreement to acquire eCential Robotics.

### [Enovis Q3 2026 earnings call transcript](https://www.tradingkey.com/news/transcripts/262292994-)

Executive talk · Damien McDonald, Chief Executive Officer · 2026-11-05

- Q3 2026 organic growth was 5%: Recon 6% and P&R 3%. U.S. Recon grew 5% (Extremities 5%, Hips and Knees 3%) and International Recon 8%, led by double-digit Shoulder growth.
- Nebula hip stem: "over 80% of new instrumentation sets going to competitive users", now the company's "top-selling stem", "in the early stages of a multiyear product cycle".
- eCential Robotics (binding offer September 1): works council consultation completed, close expected by year-end; knee robot expected "within 2 years", shoulder soon after. First Arvis shoulder cases in Europe were completed.
- CFO: adjusted gross margin 60.9% including $8 million of tariff refunds, offset by roughly $3 million of inflation tied to the Middle East conflict; adjusted EBITDA margin 18.5%, adjusted EPS $0.88 (+17%).
- Free cash flow was $35 million in the quarter; net leverage 2.9x, stepping up about 0.5 turn when eCential closes; leverage range 2.5 to 3.5x; new $200 million buyback, used "opportunistically".
- 2027: at least 50% free cash flow conversion and $100 million of cash generation reiterated; Q4 gets an extra selling day worth about 150 basis points.
- Market described as "pretty choppy" (scheduling, cancellations, patient affordability); McDonald's stance: "not being a victim to the market".
- ASC mix: a little over 25% of primary knees, about 20% of hips, shoulder in the high teens. Enovis is #3 globally in shoulder, #2 internationally.
- P&R: more than 50% of the portfolio grows mid-single digits or more; tailwinds from the NOPAIN Act (cold therapy); France and Germany under pressure; MotionMD software has a 99% customer satisfaction rating.

### [Enovis (ENOV) Q1 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/05/08/enovis-enov-q1-2026-earnings-transcript/)

Executive talk · Damien McDonald, Chief Executive Officer · 2026-05-08

- Q1 2026 sales were $589 million, up 5% reported (currency +420 basis points, selling days -240, Dr. Comfort divestiture -210); organic growth 3% (Recon 6%, P&R 1%), or 6% days-adjusted (Recon 8%, P&R 3%).
- U.S. Recon grew 8% organically, led by 10% in Extremities (ARG driving double-digit shoulder growth) and 6% in Hips and Knees; International Recon grew 3%.
- McDonald, 12 months into the job: changes to the operating model, senior leadership and incentive plans, and a "One Enovis mindset".
- Arvis launched at AAOS (March), offered by capital purchase, lease or fee per case with a volume commitment, mainly to drive implant use and competitive conversions; the first case outside the U.S. was in South Africa.
- Nebula opens a hip segment Enovis was "locked out of"; "something like 50% of our knee surgeons don't use our hip because we haven't had an offering".
- Adjusted gross margin 62% despite about $4 million of tariffs (mostly P&R); adjusted EBITDA margin 17.6%; adjusted EPS $0.89; free cash flow up $16 million year on year; guidance reaffirmed, with more than 25% free cash flow conversion.
- Middle East revenue exposure is $1 million to $2 million a month; international volumes were hit by strikes and waiting lists, but Enovis says it outgrew the market.
- Market view (IR): U.S. hips 3% to 4%, knees 4% to 5%, shoulders 5% to 7%, international recon 4% to 6%; Recon pricing "a little bit down", with ASC shift adding pressure.
- ASC is a strategic priority: primary knees over 25% in ASCs; the aim is to change the trajectory of the full offering in those facilities over 3 to 5 years.

## Questions about Enovis

### What does Enovis do?

Enovis develops, manufactures and distributes medical devices for reconstructive surgery, rehabilitation, pain management and physical therapy, through its Prevention & Recovery and Reconstructive segments.

### What is Enovis's revenue?

FY2025 net sales were $2,248.0 million. For 2026 Enovis guides to revenue of $2.32-2.35 billion.

### How many employees does Enovis have?

Enovis employed approximately 7,802 people at December 31, 2025.

### Who leads Enovis?

Damien McDonald has been CEO since March 2025 and Phillip B. Berry is CFO.

### What is Enovis's strategy?

It focuses on innovation-led growth in reconstructive implants, enabling technology such as robotics and augmented reality, ambulatory surgery centers and disciplined execution.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
